Eleonora Longhi

Eleonora Longhi

Auto-generated profile, based on publicly available information

Eleonora Longhi

Postgraduate School in Clinical Pathology and Clinical Biochemistry, Università Politecnica delle Marche, via Tronto 10/A, 60126 Ancona, Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2021 in Scandinavian Journal of Immunology
Verified
Journal Article
Open access
PDF file
MDMaria Giovanna Danieli
Maria Giovanna Danieli
MPMario Andrea Piga
Mario Andrea Piga
APAlberto Paladini
Alberto Paladini
ELEleonora Longhi
Eleonora Longhi
CMCristina Mezzanotte
Cristina Mezzanotte
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld
The coronavirus disease‐19 (COVID‐19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) challenged globally with its morbidity and mortality. A small percentage of affected patients (20%) progress into the second stage of the disease clinically presenting with severe or fatal involvement of lung, heart and vascular system, all contributing to multiple‐organ failure. The so‐called ‘cytokines storm’ is considered the pathogenic basis of severe disease and it is a target for treatment with corticosteroids, immunotherapies and intravenous immunoglobulin (IVIg). We provide an overview of the role of IVIg in the therapy of adult patients with COVID‐19 disease. After discussing the possible underlying mechanisms of IVIg immunomodulation in COVID‐19 disease, we review the studies in which IVIg was employed. Considering the latest evidence that show a link between new coronavirus and autoimmunity, we also discuss the use of IVIg in COVID‐19 and anti‐SARS‐CoV‐2 vaccination related autoimmune diseases and the post‐COVID‐19 syndrome. The benefit of high‐dose IVIg is evident in almost all studies with a rapid response, a reduction in mortality and improved pulmonary function in critically ill COVID‐19 patients. It seems that an early administration of IVIg is crucial for a successful outcome. Studies’ limitations are represented by the small number of patients, the lack of control groups in some and the heterogeneity of included patients. IVIg treatment can reduce the stay in ICU and the demand for mechanical ventilation, thus contributing to attenuate the burden of the disease.

20 October 2025 in Journal of Mosaic of Autoimmunity
Verified
Journal Article
Open access
PDF file
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld
ELEleonora Longhi
Eleonora Longhi
MSMartina Sordoni
Martina Sordoni
EBElena Buti
Elena Buti
SCSabrina Costanzo
Sabrina Costanzo
MDMaria Giovanna Danieli
Maria Giovanna Danieli
Autoimmune diseases are heterogeneous, multifactorial disorders defined by a loss of immunological tolerance to self-antigens, resulting in chronic inflammation and tissue damage. Even though the immune system dysregulation most commonly elicits physical symptoms, neuropsychiatric manifestations are frequently observed in autoimmune diseases and are associated with increased morbidity, elevated mortality, and a marked decline in health-related quality of life. Although extensively characterized in systemic lupus erythematosus (SLE) due to its epidemiological relevance and diagnostic complexity, neuropsychiatric involvement holds clinical significance across a wider spectrum of rheumatologic disorders. The frequent co-occurrence of connective tissue disorders with mood and anxiety symptoms suggests shared etiological mechanisms. The early identification of neuropsychiatric manifestations in patients with chronic autoimmune diseases represents the cornerstone of clinical management, given the substantial impact these symptoms have on individuals already burdened by debilitating conditions. We reviewed the principal neuropsychiatric manifestations associated with selected systemic autoimmune diseases: the novelty of this research lies not only in its approach to autoimmune-related neuropsychiatric symptoms but also in the special emphasis placed on the immunopathogenic mechanisms potentially responsible for these manifestations and, more significantly, on therapeutic decision-making, including an evaluation of treatment strategies targeting immune dysregulation and their potential impact on the neuropsychiatric profile, to optimize clinical outcomes and ensure patients have a comprehensive cure.

14 November 2026 in Mechanisms of Ageing and Development
Verified
Journal Article
Open access
CGChiara Giordani
Chiara Giordani
Mirko Di RosaMirko Di Rosa
Mirko Di Rosa
GMGiulia Matacchione
Giulia Matacchione
MSMatilde Sbriscia
Matilde Sbriscia
SFSonia Fantone
Sonia Fantone
JSJacopo Sabbatinelli
Jacopo Sabbatinelli

19 March 2026 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
ELEleonora Longhi
Eleonora Longhi
AÇArtan Çeka
Artan Çeka
FOFabiola Olivieri
Fabiola Olivieri
MMMarco Moretti
Marco Moretti
JSJacopo Sabbatinelli
Jacopo Sabbatinelli
Background: Heavy chain disease (HCD) is a rare plasma‐cell neoplasm frequently linked to lymphoproliferative and autoimmune disorders. Clinical presentation varies widely, with no conventional signs or symptoms. The prognosis is frequently uncertain, and there is currently no typical diagnosis or treatment. Truncated immunoglobulins' heavy chains (HCs) identification and bound light chains (LCs) exclusion are diagnostic requirements. The initial approach is laboratory‐based, mostly from protein analysis, as serum protein electrophoresis (SPE), immunotyping (IT), and immunofixation (IFE) are usually the first diagnostic steps. Methods: A panel of tests resulted in low serum protein, so SPE, IT, and IFE were conducted. The findings established a spike's presence and γ‐HC isotype, but differential diagnosis from gammopathies with LCs' low reactivity to reagents required further testing. Consequently, a molecular weight separation gel and immunoselection were executed. Results: SPE showed a 29.4% (12.9 g/L) spike central to the γ‐fraction, while IT resulted in a subtraction in the IgG window, later verified by serum IFE. Immunoselection showed no LC‐HC link, excluding a gammopathy with difficult LC identification. The molecular weight gel revealed a 160 kDa band. This rare case of HCD presents unique complexity, also due to discordant IgG3–IgG quantitation, associated angioimmunoblastic lymphoma morphology, and EBV genome. Conclusion: The aim is to draw attention to the difficulties in diagnosing HCD and stress the importance of both advanced methods and a proper laboratory approach. This is necessary to ensure prompt and effective care for a rare condition, particularly with complex presentations like this case.

6 August 2026 in Autoimmunity Reviews
Verified
Journal Article
Open access
SGSebastiano Gangemi
Sebastiano Gangemi
LGLuca Gammeri
Luca Gammeri
ELEleonora Longhi
Eleonora Longhi
Bogdanos DimitriosBogdanos Dimitrios
Bogdanos Dimitrios
MDMaria Giovanna Danieli
Maria Giovanna Danieli

11 August 2022
Verified
Book Chapter
Closed access
PDF file
MDMaria Giovanna Danieli
Maria Giovanna Danieli
APAlberto Paladini
Alberto Paladini
LPLuca Passantino
Luca Passantino
ELEleonora Longhi
Eleonora Longhi